LONDON -- Oxford BioMedica plc's share price plunged 60.27 percent to 7.35 pence (US15 cents) on Friday when the company said the Phase III trial of its cancer vaccine TroVax would not reach its primary endpoint of overall survival in renal cancer.
As a result, the product, which was partnered with Sanofi-Aventis SA in a $690 million deal agreed to in March 2007, will not meet the terms of the FDA's Special Protocol Assessment, and a further trial will be required to register TroVax in that indication.
The news follows the fourth interim review by the data safety monitoring board, carried out at the point when 190 of the patients recruited into the 733 patient study …
Комментариев нет:
Отправить комментарий